Pacritinib, an investigational oral multikinase inhibitor, improves spleen volume reduction among high-risk patients with advanced myelofibrosis, according to preliminary results from the phase 3 PERSIST-2 clinical trial.1
Investigators enrolled 311 patients with myelofibrosis whose platelet counts were less than 100,000/μL. Among the 221 patients who reached week 24, treatment with pacritinib was associated with an improved response rate in spleen volume reduction, in contrast with the best available therapies, including ruxolitinib.
The other co-primary end point of greater than 50% reduction in Total Symptom Score was not met, though preliminary data suggest a trend toward significant results.
Continue Reading
RELATED: Imetelstat Active in Myelofibrosis, But May Cause Myelosuppression
The most frequently reported treatment-emergent adverse events among patients treated with pacritinib were diarrhea, nausea, and vomiting, which were generally manageable.
Additional findings will be submitted for presentation at an upcoming scientific meeting.
Reference
- CTI Biopharma announces top-line results from PERSIST-2 phase 3 trial of pacritinib for high-risk patients with advanced myelofibrosis. CTI BioPharma website. http://investors.ctibiopharma.com/phoenix.zhtml?c=92775&p=RssLanding&cat=news&id=2197807. Updated August 29, 2016. Accessed August 29, 2016.
